Center for Cancer Nanotechnology Excellence for Translational Diagnostics

(CCNE-TD)

The Center for Cancer Nanotechnology Excellence for Translational Diagnostics (CCNE-TD), which forms the third cycle CCNE Program at Stanford University, is a consortium that has three highly synchronized Projects and three Cores. Since its initial funding in May 2006, our CCNE program has matured substantially into a strong multidisciplinary program with expertise and infrastructure to support the growing field of cancer nanomedicine. Dr. Sanjiv Sam Gambhir, MD, PhD (PI/PD) is the Chairman of the Department of Radiology at Stanford and is an expert in Molecular Imaging, Radiology and Bioengineering. Dr. Shan X. Wang, (co-PI) is a Professor of Materials Science and Engineering as well as Electrical engineering at Stanford. He has spent the major portion of his career focused on magneto nanobio-sensing. Dr. Demir Akin, DVM, PhD (Deputy Director), is an interdisciplinary scientist and a well-known Nanomedicine expert has been the Deputy Director of the Stanford CCNE Program and he continues with this responsibility in the CCNE-TD Program. Together, Drs. Gambhir, Wang and Akin provide an enormous breadth of experience ranging from fundamental nanoscience and engineering, to pre-clinical imaging, and on to translation to clinical applications of molecular imaging and cancer nanodiagnostics. The Center is composed of a highly interdisciplinary team of scientists whose expertise areas are highly synergistic and have a long collaboration history that extends to the first cycle of the NCI’s CCNE Program.  Defining it broadly, the CCNE-TD will develop and clinically translate cancer diagnostics and imaging technologies. More specifically, it has two scientific thematic focus areas: i) predicting and monitoring cancer therapy response in lung cancer and ii) merging of nano-based in vitro and in vivo diagnostics strategies as well as nano-based imaging for earlier cancer detection and prognostication for prostate cancer.